Loading
Sentiment · FY2025 Q4
| Analyst | Firm | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Craig Hettenbach | Morgan Stanley | 7 (14%) |
| Ryan MacDonald | Needham | 6 (0%) |
| Maria Ripps | Canaccord Genuity | 5 (0%) |
| Eric Percher | Nephron Research | 5 (0%) |
| Brian Tanquilut | Jefferies | 4 (0%) |
| Daniel Grosslight | Citigroup | 4 (50%) |
| Jonna Kim | TD Cowen | 3 (0%) |
| Aaron Kessler | Seaport Research Partners | 2 (0%) |
| Justin Patterson | KeyBanc Capital Markets | 2 (0%) |
| Dave Larsen | BTIG | 2 (50%) |
| Firm | Analysts | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Morgan Stanley | 1 | 7 (14%) |
| Needham | 1 | 6 (0%) |
| Nephron Research | 1 | 5 (0%) |
| Canaccord Genuity | 1 |
| 5 (0%) |
| Jefferies | 1 | 4 (0%) |
| Citigroup | 1 | 4 (50%) |
| TD Cowen | 1 | 3 (0%) |
| KeyBanc Capital Markets | 1 | 2 (0%) |
Hims & Hers grew revenue 73% year-over-year to $545 million in the second quarter of 2025, with adjusted EBITDA of $82 million holding margin north of 15% even after roughly $7 million of severance and sign-on costs. Growth broadened across dermatology, oral weight loss and daily sexual health, each up more than 55%, offsetting a deliberate offboarding of commercially available GLP-1 dosages that pulled monthly average revenue per subscriber down to $74 from $84. Management leaned into expansion, closing the ZAVA acquisition to enter the U.K. and Europe, seeding a 2026 Canada launch, and outlining new hormonal-health, lab-testing and longevity specialties on the path to its 2030 targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. Full-year guidance was reiterated at $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA, with free cash flow of negative $69 million and a step down to an 11% third-quarter margin reflecting a deliberate investment period in marketing and technology.
Revenue Growth | Product Launch | Demand | Regulation Policy | Margin | Guidance Reliability | Competitive Dynamics | Geographic Expansion | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 3 | 4 | 2 | 2 | ||||
| 2025Q1 | 4 | 6 | 1 | 3 | 1 | 2 | ||
| 2025Q2 | 5 | 1 | 4 | 1 | 4 | 1 | 2 | |
| 2025Q3 | 1 | 1 | 4 | 2 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | |
|---|---|---|---|---|
| Revenue Growth | 3 | 4 | 5 | 1 |
| Product Launch | 4 | 6 | 1 | 1 |
| Demand | 2 | 1 | 4 | 4 |
| Regulation Policy | 2 | 3 | ||
| Margin | 1 | 1 | 2 | |
| Guidance Reliability | 4 | |||
| Competitive Dynamics | 2 | 1 | ||
| Geographic Expansion | 2 | 1 |
What HIMS and other companies said about each other on FY2025 Q2 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“In July, we closed our acquisition of ZAVA, expanding our presence in the U.K. and establishing a foundation in other strategic markets such as Germany, Ireland and France.”
Hims & Hers closed its acquisition of UK telehealth company ZAVA to enter the U.K. and seed Germany, Ireland and France, expecting at least $50 million of net incremental revenue in the remainder of 2025 and a foundation for its 2026 Canada launch.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $481M | +95.1% | $0.11 | — | 3.9% | 5.4% | $60M |
| FY2025 Q1 | $586M | +110.7% | $0.20 | +300.0% | 9.9% | 8.4% | $50M |
| FY2025 Q2 | $545M | +72.6% | $0.17 | +200.4% | 4.9% | 7.8% | $-69M |
| FY2025 Q3 | $599M | +49.2% | $0.06 | -80.2% | 2.0% | 2.6% | $91M |
| FY2025 Q4 | $618M | +28.4% | $0.08 | -27.3% | 1.5% | 3.3% | $821,000 |
| FY2026 Q1 | $608M | +3.8% | $-0.40 | -300.0% | -2.7% | -15.1% | $53M |
| FY2026 Q2 | $753M | +38.2% | $-0.37 | -317.6% | -12.9% | -11.5% | $-55M |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
HIMS Hims & Hers Health, Inc. | 9 | +72.6% | |
| DVA DaVita | 6 | +6.0% | |
| HCA HCA Healthcare | 8 | +6.4% | |
| SOLV Solventum | 9 | +3.8% | |
| UHS Universal Health Services | 9 | +9.6% |